Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cisplatin and Topotecan Followed by Paclitaxel and Carboplatin in Advanced Ovarian Cancer
NCT00005051Phase 2Completed
- Sponsor
- NYU Langone Health
- Start
- Aug 1999
- Primary completion
- Mar 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of topotecan in ovarian cancer, sponsored by NYU Langone Health. Primary endpoints: Toxicity and tolerance, Objective Response Rate and 1 more. Started Aug 1999; status: completed.
02
Drugs
topotecan
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT00005051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005051.